ForeverLabs
ServicesProvidersScienceMission
Schedule your free consultation

Regenerative Medicine Insights

Clinical trials, aesthetic applications, regulatory updates, research studies, and industry insights from the world of regenerative medicine

K

Latest Articles

Active Filters:
Tag: Immunosuppression
AI generated image for: BM-MSC-derived migrasomes reverse stroke-induced thymic atrophy and immunosuppression via Pin1 delivery to thymic epithelial cells
Clinical
Nov 22, 2025
1 min read
Biomedcentral
BM-MSC-derived migrasomes reverse stroke-induced thymic atrophy and immunosuppression via Pin1 delivery to thymic epithelial cells
The authors show that bone marrow–derived mesenchymal stem cells (BM-MSC) can reverse stroke-induced thymic atrophy, restore thymic structure, and normalize peripheral T-cell populations in a mouse tMCAO model.
clinicalImmunosuppression

Stay in touch

Shop

Annual planLifetime planClient Login

Learn

ArticlesBlogFAQ

Careers

About usPrivacy policyPressTerms of Use

Questions

For physiciansPartner with usCareersContact us(888) 732-2375
ForeverLabs

Follow Us

FacebookXInstagramLinkedInYouTube

FDA and Stem Cell Therapies

The U.S. Food and Drug Administration (FDA) regulates stem cell therapies as biological products to ensure their safety and efficacy. The FDA requires that stem cell therapies undergo rigorous clinical trials to demonstrate safety and effectiveness before approval. Patients considering stem cell treatments should consult with their healthcare providers about FDA-approved options and be cautious of unproven therapies that have not undergone proper regulatory review.